About Dompé
Dompé is a Healthcare company based in Milan (Italy) founded in 1940. Therapies are developed for ophthalmology, oncology, diabetes, and organ transplantation. Its website dompe.com draws about 40 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals. Its legal entity is DOMPE US INC.
Company details
Dompé is focussed on the development of treatment solutions for rare and often orphan diseases in areas such as diabetes, organ transplants, ophthalmology and oncology. Its product candidates are either SMW GPCRs modulators or Biotech NCEs. Its portfolio includes Reparixin, a pancreatic islet and lung transplant in phase 3 trials; Ladarixin in phase1 trials for onset type 1 diabetes; rhNGF (recombinant human nerve growth factor) for keratitis (phase 3), retinitis pigmentosa (phase 2) and Glaucoma (phase 1) ; Reparixin in phase 2 for breast cancer and Gabapentin in phase 3 trials for pediatric pain.
- Latest Funding Round$1.18M (USD), Grant
Nov 2020
- Investors
Funding Insights of Dompé
- Total Rounds 3
- Last Round Grant — $1.18M
- First Round $334,555
(Sep 2015)
- Investors Count 1
All 3 funding rounds of Dompé with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $1.18M | Grant | – | – | |
| Apr 2020 | $448,381 | Grant | – | – | |
| Sep 2015 | $334,555 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Dompé
Dompé has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Dompé
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dompé
132 people are tracked at Dompé (54 in leadership, 78 in team).
| Name | Role | Group |
|---|---|---|
Sarah Wilting | Associate Scientific Director, Ophthalmics | Leadership |
Sergio Dompé | Executive President | Leadership |
Eriona Gjinukaj | COO | Leadership |
Giuseppe Andreano | CFO | Leadership |
Marcello Allegretti | Chief Scientific Officer | Leadership |
Flavio Mantelli | Chief Strategy & Innovation Officer | Leadership |
Mahindra Makhija | Head Of Translational Research - Exscalate Drug Discovery And Development | Leadership |
Emanuele Chirivino | Head Of Corporate Quality System | Leadership |
Samuel Hamp | Associate Director Business Operations And External Alliance | Leadership |
Suresh K. | Head Of Data Management & Statistical Programming - Senior Director | Leadership |
Marybeth Howard | Vice President Of Sales | Leadership |
Gianluca Rossetti | Strategic Planning & Corporate Business Development Director | Leadership |
Jacqueline Quintero | Regional Sales Director, Northwest | Leadership |
Stefano Alberti | Demand Planning & Distribution Associate Director | Leadership |
Janko P. | Head Of Global Procurement | Leadership |
Lucas Medina | Regional Sales Director - South, Dompé US | Leadership |
Irene Guerrieri | Pharma Unit Associate Director | Leadership |
Manuela Leone | Senior VP Scientific Advisor | Leadership |
Stefania Iaggia | Head Of Global Supply Chain | Leadership |
Adam Apprill | Vice President Of People & Culture, Dompe US | Leadership |
112 more people are available in the full profile.
Complete people profiles for Dompé
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Dompé
3 dated milestones of Dompé across 80 years, from founding to its latest funding, stage changes and deals.
- Founded Dompé is founded.
- Funding First funding round of $335K.
- Funding Latest funding round, Grant, of $1.2M.
Web traffic of Dompé
The website of Dompé (dompe.com) receives about 40.4K visits a month and ranks #1,197,595 among all websites worldwide, #1,504 in Biotechnology and Pharmaceuticals.
- Monthly visits40.4K
▲ 69.5% vs previous month
- Unique visitors10.4K
per month
- Global rank#1,197,595
among all websites
- Category rank#1,504
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.7
- Average visit26 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Dompé. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
farvima.it | farvima.it | 100% | #5,097,698 | – | |
| philogen.com | 97% | 5.4K | #3,289,130 | View details | |
nowfarma.it | nowfarma.it | 70% | – | ||
farmaciarubino.net | farmaciarubino.net | 63% | #844,286 | – | |
semprefarmacia.it | semprefarmacia.it | 34% | #61,911 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dompé
Complete news archive for Dompé
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dompé
Dompé was founded in 1940 and raised its 1st funding round 75 years after it was founded.
Dompé is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Dompé is focussed on the development of treatment solutions for rare and often orphan diseases in areas such as diabetes, organ transplants, ophthalmology and oncology. Its product candidates are either SMW GPCRs modulators or Biotech NCEs. Its portfolio includes Reparixin, a pancreatic islet and lung transplant in phase 3 trials; Ladarixin in phase1 trials for onset type 1 diabetes; rhNGF (recombinant human nerve growth factor) for keratitis (phase 3), retinitis pigmentosa (phase 2) and Glaucoma (phase 1) ; Reparixin in phase 2 for breast cancer and Gabapentin in phase 3 trials for pediatric pain.
Dompé has 1 investor. Key investors include European Union.
Dompé operates through Dompe Us Inc.